ADHD Predominantly Inattentive Type Clinical Trial
Official title:
Cognitive Impairment in Pediatric Onset Multiple Sclerosis: Research of Biomarkers Predictive of Cognitive Impairment Progression
Verified date | June 2017 |
Source | University of Bari |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Computer-assisted rehabilitation of attention deficits in pediatric Multiple Sclerosis and ADHD patients recruited during the study "Cognitive impairment in Pediatric Onset Multiple Sclerosis: research of biomarkers predictive of cognitive impairment progression".
Status | Completed |
Enrollment | 36 |
Est. completion date | April 30, 2016 |
Est. primary completion date | April 30, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 17 Years |
Eligibility |
Inclusion Criteria: - POMS diagnosed according to the most recent diagnostic criteria; - age <18 years; - Expanded Disability Status Scale (EDSS) score =5.5; - impairment on at least 2/4 attention tests defined as scores <1.5 standard deviation (SD) of normative values; - ADHD patients with the subtype inattention; - ADHD diagnosis performed according the DSM-5 criteria and the NIMH Collaborative Multisite Multimodal Treatment Study of Children With Attention- Deficit/Hyperactivity Disorder (MTA) - Swanson, Nolan, and Pelham IV Rating Scale (MTA-SNAP-IV), Conner's Parent Rating Scale Revised (CPRS-R), Conner's Teacher Rating Scale Revised (CTRS-R), Child Behavior Checklist (CBCL), Kiddie Schedule for Affective Disorder and Schizophrenia (K-SADS); - age <18 years; - impairment on at least 2/4 attention tests defined as scores <1.5 standard deviation (SD) of normative values; Exclusion Criteria: - severe cognitive impairment (performance =2.0 SD of normative values); - severe visual loss (unable to read Times New Roman font 16 with the best correction); - major psychiatric illness; - alcohol or substance abuse; - education <5 years; - previous cognitive rehabilitation training; - ongoing relapse or steroid treatment during the 30 days preceding enrollment; - ADHD subtype hyperactivity; - previously exposure or treatment with any psychotropic drug. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Pietro Iaffaldano |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | to evaluate the effect of the cognitive training on neuropsychological performances. | A global score, defined Cognitive Impairment Index (CII), allowing the evaluation of changes in cognitive performances independently by the number of cognitive tests failed at the neuropsychological evaluation, will be obtained using the mean and SD from the normative values for each test. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04090983 -
Cognitive-Behavioral Therapy for Adults With Attention-Deficit/Hyperactivity Disorder Inattentive Presentation
|
N/A | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Completed |
NCT01554046 -
The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT05452954 -
Psychosocial ADHD Interventions - Brief Parent Training
|
N/A | |
Recruiting |
NCT04504890 -
Ocular-vestibular Biomarker Identification for ADHD
|
||
Recruiting |
NCT06299189 -
A Therapist Guided Internet-delivered Treatment for Adults With ADHD (Attention Deficit / Hyperactivity Disorder) - an Open Effectiveness Trial in Routine Care
|
N/A | |
Recruiting |
NCT04729439 -
Technology-Enhanced Executive Functioning Intervention for ADHD
|
Phase 1 | |
Completed |
NCT01685281 -
Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder
|
Phase 2 |